Core Insights - Medtronic's BrainSense™ Adaptive Deep Brain Stimulation (aDBS) has been recognized by TIME as one of the Best Inventions, marking a significant advancement in healthcare technology for Parkinson's disease patients [1][4]. Company Overview - Medtronic plc is a global leader in healthcare technology, headquartered in Galway, Ireland, with over 95,000 employees across more than 150 countries [6]. - The company has been a pioneer in deep brain stimulation (DBS) therapy for over 30 years, serving more than 200,000 patients with movement disorders [5]. Product Innovation - The BrainSense™ aDBS system is the world's first closed-loop DBS system, which personalizes therapy based on real-time brain activity, reducing the need for manual adjustments by patients [2][4]. - Medtronic has spent over 20 years developing this sensing-enabled DBS system, integrating therapeutic brain-computer interface (BCI) technology into its offerings [4]. Clinical Validation - The pivotal ADAPT-PD study published in JAMA Neurology demonstrated the clinical effectiveness, long-term safety, and patient preference for the BrainSense™ aDBS system [4]. - More than 1,000 patients worldwide have already received the adaptive therapy since its approval by CE Mark and U.S. FDA earlier this year [4]. Industry Recognition - TIME's annual Best Inventions list highlights innovations that significantly impact daily life, with Medtronic's technology being recognized for its intentional innovation and responsiveness to patient needs [3][5].